CA2520475A1 - Particules a charge medicamenteuse ciblant les tumeurs - Google Patents

Particules a charge medicamenteuse ciblant les tumeurs Download PDF

Info

Publication number
CA2520475A1
CA2520475A1 CA002520475A CA2520475A CA2520475A1 CA 2520475 A1 CA2520475 A1 CA 2520475A1 CA 002520475 A CA002520475 A CA 002520475A CA 2520475 A CA2520475 A CA 2520475A CA 2520475 A1 CA2520475 A1 CA 2520475A1
Authority
CA
Canada
Prior art keywords
tumor
therapeutic agent
composition
microparticles
paclitaxel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002520475A
Other languages
English (en)
Other versions
CA2520475C (fr
Inventor
Jessie L.-S. Au
M. Guillaume Wientjes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2520475A1 publication Critical patent/CA2520475A1/fr
Application granted granted Critical
Publication of CA2520475C publication Critical patent/CA2520475C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Nanotechnology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
CA2520475A 2003-04-03 2004-04-02 Particules a charge medicamenteuse ciblant les tumeurs Expired - Fee Related CA2520475C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46082703P 2003-04-03 2003-04-03
US60/460,827 2003-04-03
PCT/US2004/010230 WO2004089291A2 (fr) 2003-04-03 2004-04-02 Particules a charge medicamenteuse ciblant les tumeurs

Publications (2)

Publication Number Publication Date
CA2520475A1 true CA2520475A1 (fr) 2004-10-21
CA2520475C CA2520475C (fr) 2012-10-09

Family

ID=33159807

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2520475A Expired - Fee Related CA2520475C (fr) 2003-04-03 2004-04-02 Particules a charge medicamenteuse ciblant les tumeurs

Country Status (8)

Country Link
EP (1) EP1608359A4 (fr)
JP (1) JP4927535B2 (fr)
KR (1) KR100849911B1 (fr)
CN (2) CN1816331B (fr)
AU (1) AU2004228008B2 (fr)
CA (1) CA2520475C (fr)
IL (1) IL171185A (fr)
WO (1) WO2004089291A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018067545A1 (fr) * 2016-10-04 2018-04-12 University Of Florida Research Foundation, Inc. Nanoparticules chondroprotectrices pour le traitement de l'ostéoarthrite

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526322A (ja) * 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
EP1865924B1 (fr) * 2005-03-31 2015-12-09 Lidds Ab Methode de traitement de maladies prostatiques par administration locale de substances actives
BRPI0600285C1 (pt) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
JP2007277217A (ja) * 2006-03-17 2007-10-25 Fujifilm Corp 薬剤を均一に封入した生分解性マトリックス
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
EP2322235A1 (fr) * 2006-11-20 2011-05-18 Lutonix, Inc. Revêtements de libération de médicament pour dispositifs médicaux
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
EP2074988B1 (fr) 2007-12-28 2018-03-14 Industrial Technology Research Institute Composition à libération prolongée et son procédé de fabrication
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
WO2009116556A1 (fr) * 2008-03-19 2009-09-24 富士フイルム株式会社 Composition pharmaceutique pour injection
WO2010005726A2 (fr) 2008-06-16 2010-01-14 Bind Biosciences Inc. Nanoparticules polymères thérapeutiques avec inhibiteurs de mtor et procédés de fabrication et d’utilisation associés
EA020753B1 (ru) 2008-06-16 2015-01-30 Бинд Терапьютикс, Инк. Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
JP6363320B2 (ja) 2008-06-16 2018-07-25 ファイザー・インク 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
WO2010075072A2 (fr) 2008-12-15 2010-07-01 Bind Biosciences Longues nanoparticules circulantes pour la libération prolongée d'agents thérapeutiques
TR201906255T4 (tr) 2009-12-11 2019-05-21 Pfizer Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar.
EP2515942B1 (fr) * 2009-12-15 2020-02-12 Pfizer Inc. Compositions de nanoparticules polymères à visée thérapeutique à base de copolymères à température de transition vitreuse élevée ou poids moléculaires élevés
KR101314579B1 (ko) * 2011-04-07 2013-10-10 광주과학기술원 파크리탁셀이 선적된 고분자 나노입자 및 그 제조방법
JP2013053103A (ja) * 2011-09-05 2013-03-21 Ltt Bio-Pharma Co Ltd 薬物を封入した肝臓集積性ナノ粒子
WO2013124867A1 (fr) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
AU2013315118B2 (en) 2012-09-17 2017-10-05 Pfizer Inc. Process for preparing therapeutic nanoparticles
US10143700B2 (en) 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
ME02860B (fr) 2013-09-16 2018-04-20 Astrazeneca Ab Nanoparticules polymères thérapeutiques et leurs procédés de fabrication et d'utilisation
EP3116547B1 (fr) 2014-03-14 2019-06-05 Pfizer Inc Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation
EP3242653A1 (fr) * 2015-01-05 2017-11-15 Boston Scientific Scimed Inc. Microsphère biodégradable éluant un médicament pour le traitement de tumeurs solides
ES2833749T3 (es) 2015-06-04 2021-06-15 Crititech Inc Partículas de taxano y su uso
WO2017083717A1 (fr) * 2015-11-11 2017-05-18 Qrono, Inc. Compositions pharmaceutiques à libération prolongée et méthodes d'utilisation
CN114767860A (zh) 2016-04-04 2022-07-22 克里蒂泰克公司 实体肿瘤治疗方法
CN106075535B (zh) * 2016-06-14 2019-04-02 武汉纺织大学 一种医用敷料及其制备方法
WO2018011040A1 (fr) * 2016-07-13 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Microparticules de plga chargées de fluoroquinolone pour le traitement de maladies respiratoires.
CN107049984A (zh) * 2017-03-14 2017-08-18 武汉理工大学 一种载紫杉醇聚乳酸‑羟基乙酸微球的制备方法
KR102024273B1 (ko) * 2017-03-27 2019-11-04 주식회사 피에프디 약물 작용 관리 장치 및 방법
EP3615145B1 (fr) 2017-06-09 2024-05-15 Crititech, Inc. Compositions pour utilisation dans le traitement des kystes épithéliaux par injection intrakystique de particules antinéoplasiques
JP6840869B2 (ja) 2017-06-14 2021-03-10 クリチテック，インコーポレイテッド 肺障害の治療方法
CN111278436A (zh) 2017-10-03 2020-06-12 克里蒂泰克公司 局部递送抗肿瘤颗粒与全身递送免疫治疗剂相结合用于治疗癌症
US20190209515A1 (en) * 2018-01-05 2019-07-11 Crititech, Inc. Treatment of Bladder Cancer by Intratumoral Injection of Taxane Particles
GB201800912D0 (en) * 2018-01-19 2018-03-07 Ucl Business Plc Compositions for the treatment of a disease of the urinary tract and treatment of a disease involving the intracellular delivery of the particle
WO2019231499A1 (fr) * 2018-05-31 2019-12-05 Crititech, Inc. Utilisation d'agents antinéoplasiques pour stimuler le système immunitaire pour le traitement du cancer
WO2020072090A1 (fr) * 2018-10-03 2020-04-09 Crititech, Inc. Utilisation d'agents antinéoplasiques pour stimuler le système immunitaire pour la production de structures lymphoïdes tertiaires (tls)
EP3750523A1 (fr) * 2019-06-13 2020-12-16 CAPNOMED GmbH Système de distribution de substances actives
EP3750524A1 (fr) * 2019-06-13 2020-12-16 CAPNOMED GmbH Administration retardée et modifiée de médicaments anti-cancer
WO2022075318A1 (fr) * 2020-10-08 2022-04-14 学校法人関西医科大学 Marqueur d'évaluation reflétant l'efficacité d'une composition de traitement du cancer
WO2022082196A1 (fr) * 2020-10-14 2022-04-21 Foundry Therapeutics, Inc. Dépôts implantables de libération localisée, prolongée et contrôlée d'agents thérapeutiques pour traiter le cancer ainsi que des états associés
WO2022187839A1 (fr) * 2021-03-05 2022-09-09 H. Lee Moffitt Cancer Center And Research Institute Inc. Polythérapie pour traiter des tumeurs mutantes sensibles à la température
CN115770224B (zh) * 2023-01-17 2023-04-18 中国人民解放军总医院第一医学中心 一种携载紫杉醇药物的丙烯酸微球及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US20020164374A1 (en) * 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
AU777620B2 (en) * 1999-04-09 2004-10-21 Jessie L.S. Au Methods and compositions for enhancing delivery of therapeutic agents to tissues
US6287588B1 (en) * 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6444227B1 (en) * 1999-08-05 2002-09-03 Roche Vitamins Inc. Process for preparing fat soluble beadlets
WO2002049620A2 (fr) * 2000-12-21 2002-06-27 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophobic active agents
CA2445763A1 (fr) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions et procedes pour le traitement d'etats inflammatoires par des proteines ou polysaccharides contenant des agents anti-microtubules

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018067545A1 (fr) * 2016-10-04 2018-04-12 University Of Florida Research Foundation, Inc. Nanoparticules chondroprotectrices pour le traitement de l'ostéoarthrite
US10993919B2 (en) 2016-10-04 2021-05-04 University Of Florida Research Foundation, Inc. Chondroprotective nanoparticles for the treatment of osteoarthritis

Also Published As

Publication number Publication date
AU2004228008B2 (en) 2008-11-06
AU2009200463A1 (en) 2009-03-05
CN1816331B (zh) 2012-08-08
JP4927535B2 (ja) 2012-05-09
EP1608359A2 (fr) 2005-12-28
KR20060006911A (ko) 2006-01-20
CN1816331A (zh) 2006-08-09
AU2004228008A1 (en) 2004-10-21
WO2004089291A3 (fr) 2005-04-21
WO2004089291A2 (fr) 2004-10-21
CN102697737B (zh) 2014-03-19
IL171185A (en) 2013-07-31
CN102697737A (zh) 2012-10-03
CA2520475C (fr) 2012-10-09
EP1608359A4 (fr) 2011-08-17
KR100849911B1 (ko) 2008-08-04
JP2006522148A (ja) 2006-09-28

Similar Documents

Publication Publication Date Title
CA2520475A1 (fr) Particules a charge medicamenteuse ciblant les tumeurs
Bahadur et al. Current promising treatment strategy for glioblastoma multiform: A review
US8043631B2 (en) Tumor targeting drug-loaded particles
US8221779B2 (en) Compositions and methods for the delivery of poorly water soluble drugs and methods of treatment
KR20040058199A (ko) 폴리 양이온성 폴리머 및 음전하를 띠는 약리학적 활성화합물을 포함하는 제어 방출 약물 전달 조성물
Jaferian et al. Colon cancer targeting using conjugates biomaterial 5-flurouracil
US20040126400A1 (en) Delivery of therapeutic compounds via microparticles or microbubbles
CA2993823C (fr) Compositions d'implant destinees a l'apport unidirectionnel de composes therapeutiques au cerveau
Ramazani et al. Locoregional cancer therapy using polymer-based drug depots
US11779644B2 (en) Sensitizing cells to proton radiation
JP2003501379A (ja) ガン治療のための薬剤を充填したナノパーティクルの使用
Tang et al. Enhanced efficacy of local etoposide delivery by poly (ether-anhydride) particles against small cell lung cancer in vivo
EP2074988B1 (fr) Composition à libération prolongée et son procédé de fabrication
WO2001010416A1 (fr) Procede d'administration d'un agent chimiotherapeutique a une tumeur solide
WO2010072109A1 (fr) Système à libération prolongée pour médicament antitumoral
CN1969820A (zh) 抗癌药物组合物
Sabra et al. Soliciting the oral route as a logical approach to managing colon cancer
US20240139113A1 (en) Lipid nanoparticle with target integrin function and uses thereof
JP2001511775A (ja) 微粒子および癌処置での使用
TW202416935A (zh) 一種具有標靶整合素功能之脂質奈米粒子及其用途
US20120156128A1 (en) Controllable release composition and method for preparing same
WO2021150943A1 (fr) Microsphères chargées de microcristaux de trioxyde d'arsenic
WO2019200382A1 (fr) Compositions de nanoparticules et procédés d'utilisation d'inhibiteur de parp pour le traitement du cancer
CN101002729A (zh) 含血管抑制剂的抗癌缓释剂
CN101336898A (zh) 同载铂类药物及其增效剂的抗癌缓释剂

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180403